- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Authors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Tag Archives: biotechnology
BIO’s Amicus Brief: Microsoft v. i4i
The Biotechnology Industry Organization, along with AUTM and CropLife International, filed an amicus brief in the Microsoft v. i4i Supreme Court case. This case is widely viewed as one of the most fundamental and important patent cases to reach the Supreme Court in probably a decade. Most basically, this case is about the level of certainty a jury or judge must have before finding a patent invalid in litigation. Historically, the law has required a high level Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: amicus brief, AUTM, BIO, biotechnology, Biotechnology Industry Organization, burden of proof, clear and convincing evidence, CropLife, i4i, Microsoft, Microsoft v. i4i, patent, Patent and Trademark Office, preponderance of the evidence, PTO, Supreme Court, USPTO
Tags: amicus brief, AUTM, BIO, biotechnology, Biotechnology Industry Organization, burden of proof, clear and convincing evidence, CropLife, i4i, Microsoft, Microsoft v. i4i, patent, Patent and Trademark Office, preponderance of the evidence, PTO, Supreme Court, USPTO
BIO’s Intellectual Property Counsels Committee Seattle Meeting Topics
Join us for BIO’s Intellectual Property Counsels Committee Meeting in Seattle April 13-15. You can find the session topics below. Whose Rights Are They, Anyway? Implications from and a Discussion on Stanford v. Roche The pending Supreme Court review of Stanford v. Roche has brought out multiple perspectives on the disposition of ownership rights in federally funded inventions under Bayh-Dole. This session will explore the different interpretations of the Act’s provisions, and their practical implications Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
Biotech, Gates Foundation, and Global Health
Great interview by Gene Quinn with Erik Iverson, Associate General Counsel with the Bill & Melinda Gates Foundation. A summary article is on BIOtech Now and the full interview can be found on IPWatchdog.com. Highlights: Iverson told me in no uncertain terms, “[A] fundamental premise at the foundation is that we absolutely respect intellectual property rights. We recognize their importance and we certainly recognize the importance of companies and their involvement in developing products and having Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
BIO Hails Senate Passage of America Invents Act
BIO Hails Senate Passage of America Invents Act Bipartisan, consensus-oriented approach will strengthen nation’s patent system and spur innovation, job creation Washington, D.C. (March 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage today of the America Invents Act (S. 23) by the U.S. Senate: “BIO commends the Senate for its overwhelming passage of the America Invents Act by a vote of 95-5. We appreciate Read More >
2011 BIO International Convention Super Sessions
2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: BIO, BIO International Convention, Bio-Innovation Scorecard, Biologics, biotechnology, Biotechnology Industry Organization, Biotechnology Industry Report, Biotechnology Innovation Ecosystem, Biotechnology Trade Expo, Burrill, Campbell Alliance, Dealmakers' Intentions, Eli Lilly and Company, emerging markets, Ernst & Young, Fareed Zakaria, global biotech, Jim Greenwood, Merck, Scientific American, State-of-the-Industry Report, Super Sessions
Tags: BIO, BIO International Convention, Bio-Innovation Scorecard, Biologics, biotechnology, Biotechnology Industry Organization, Biotechnology Industry Report, Biotechnology Innovation Ecosystem, Biotechnology Trade Expo, Burrill, Campbell Alliance, Dealmakers' Intentions, Eli Lilly and Company, emerging markets, Ernst & Young, Fareed Zakaria, global biotech, Jim Greenwood, Merck, Scientific American, State-of-the-Industry Report, Super Sessions
